Vitamin D supplements and prevention of cancer and cardiovascular disease

New England Journal of Medicine

Volumn 380, Issue 1, 2019, Pages 33-44

  Manson, JoAnn E ^a,b   Cook, Nancy R ^a,b   Lee, I Min ^a,b   Christen, William ^a   Bassuk, Shari S ^a   Mora, Samia ^a   Gibson, Heike ^a   Gordon, David ^a   Copeland, Trisha ^a   D'Agostino, Denise ^a   Friedenberg, Georgina ^a   Ridge, Claire ^a   Bubes, Vadim ^a   Giovannucci, Edward L ^a,b   Willett, Walter C ^a,b   Buring, Julie E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; OMEGA 3 ACID ETHYL ESTER; PLACEBO; 25-HYDROXYVITAMIN D; VITAMIN; VITAMIN D;

AGED; ALL CAUSE MORTALITY; ARTICLE; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER STAGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MULTICENTER STUDY; NEPHROLITHIASIS; PATIENT COMPLIANCE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TUMOR INVASION; UNITED STATES; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DIETARY SUPPLEMENT; INCIDENCE; MIDDLE AGED; MORTALITY; NEOPLASM; TREATMENT FAILURE;

AGED; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT FAILURE; VITAMIN D; VITAMINS;

EID: 85057616422     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1809944     Document Type: Article

References (40)

1. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press, 2011.
2. LeFevre ML. Screening for vitamin D deficiency in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015; 162: 133-40.
3. Kantor ED, Rehm CD, Du M, White E, Giovannucci EL. Trends in dietary supplement use among US adults from 1999-2012. JAMA 2016; 316: 1464-74.
4. Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012; 33: 159-71.
5. Yin L, Ordóñez-Mena JM, Chen T, Schöttker B, Arndt V, Brenner H. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and metaanalysis. Prev Med 2013; 57: 753-64.
6. Zhang R, Li B, Gao X, et al. Serum 25-hydroxyvitamin D and the risk of cardiovascular disease: dose-response metaanalysis of prospective studies. Am J Clin Nutr 2017; 105: 810-9.
7. Moyer VA. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014; 160: 558-64.
8. Manson JE, Bassuk SS. Vitamin D research and clinical practice: at a crossroads. JAMA 2015; 313: 1311-2.
9. Keum N, Giovannucci E. Vitamin D supplements and cancer incidence and mortality: a meta-analysis. Br J Cancer 2014; 111: 976-80.
10. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev 2014; 6: CD007469.
11. Manson JE, Cook NR, Lee I-M, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 2019; 380:23-32.
12. Bassuk SS, Manson JE, Lee IM, et al. Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL). Contemp Clin Trials 2016; 47: 235-43.
13. Binkley N, Carter GD. Toward clarity in clinical vitamin D status assessment: 25(OH)D assay standardization. Endocrinol Metab Clin North Am 2017; 46: 885-99.
14. Fritz AG, Percy C, Jack A, et al. International classification of diseases for oncology (ICD-O). 3rd ed. Geneva: World Health Organization, 2000.
15. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020-35.
16. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial - TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
17. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326: 469.
18. Wactawski-Wende J, Morley Kotchen J, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354: 684-96.
19. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85: 1586-91.
20. Avenell A, MacLennan GS, Jenkinson DJ, et al. Long-term follow-up for mortality and cancer in a randomized placebocontrolled trial of vitamin D(3) and/or calcium (RECORD trial). J Clin Endocrinol Metab 2012; 97: 614-22.
21. Lappe J, Watson P, Travers-Gustafson D, et al. Effect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA 2017; 317: 1234-43.
22. Scragg R, Khaw KT, Toop L, et al. Monthly high-dose vitamin D supplementation and cancer risk: a post hoc analysis of the Vitamin D Assessment randomized clinical trial. JAMA Oncol 2018 July 19 (Epub ahead of print).
23. Hollis BW, Wagner CL. Clinical review: the role of the parent compound vitamin D with respect to metabolism and function - why clinical dose intervals can affect clinical outcomes. J Clin Endocrinol Metab 2013; 98: 4619-28.
24. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014; 14: 342-57.
25. Mondul AM, Weinstein SJ, Layne TM, Albanes D. Vitamin D and cancer risk and mortality: state of the science, gaps, and challenges. Epidemiol Rev 2017; 39: 28-48.
26. McCullough ML, Zoltick ES, Weinstein SJ, et al. Circulating vitamin D and colorectal cancer risk: an international pooling project of 17 cohorts. J Natl Cancer Inst 2018 June 14 (Epub ahead of print).
27. Bauer SR, Hankinson SE, Bertone-Johnson ER, Ding EL. Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. Medicine (Baltimore) 2013; 92: 123-31.
28. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846-54.
29. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303: 1815-22.
30. Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M. Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am J Clin Nutr 2014; 100: 746-55.
31. Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment Study: a randomized clinical trial. JAMA Cardiol 2017; 2: 608-16.
32. Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and metaanalysis. J Clin Endocrinol Metab 2011; 96: 1931-42.
33. Rejnmark L, Bislev LS, Cashman KD, et al. Non-skeletal health effects of vitamin D supplementation: a systematic review on findings from meta-analyses summarizing trial data. PLoS One 2017; 12(7): e0180512.
34. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2014; 1: CD007470.
35. Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2014; 2: 307-20.
36. Shapses SA, Lee EJ, Sukumar D, Durazo-Arvizu R, Schneider SH. The effect of obesity on the relationship between serum parathyroid hormone and 25-hydroxyvitamin D in women. J Clin Endocrinol Metab 2013; 98: E886-E890.
37. Drincic AT, Armas LA, Van Diest EE, Heaney RP. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity (Silver Spring) 2012; 20: 1444-8.
38. Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018; 392: 387-99.
39. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 2015; 15: 484-98.
40. Bassuk SS, Manson JE. Randomized clinical trials of vitamin D, with a focus on the VITamin D and Omeg A-3 TriaL (VITAL). In: Feldman D, Pike JW, Bouillon R, Giovannucci E, Goltzman D, Hewison M, eds. Vitamin D, volume 2: health, disease, and therapeutics. 4th ed. San Diego CA: Academic Press, 2018: 167-76.